Leclerc S - Search Results

1

Inhibition of cyclin-dependent kinases by purine analogues.

Veselý J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S, et al. Veselý J, et al. Among authors: leclerc s. Eur J Biochem. 1994 Sep 1;224(2):771-86. doi: 10.1111/j.1432-1033.1994.00771.x. Eur J Biochem. 1994. PMID: 7925396 Free article.

2

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.

De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. De Azevedo WF, et al. Among authors: leclerc s. Eur J Biochem. 1997 Jan 15;243(1-2):518-26. doi: 10.1111/j.1432-1033.1997.0518a.x. Eur J Biochem. 1997. PMID: 9030780 Free article.

3

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

Havlícek L, Hanus J, Veselý J, Leclerc S, Meijer L, Shaw G, Strnad M. Havlícek L, et al. Among authors: leclerc s. J Med Chem. 1997 Feb 14;40(4):408-12. doi: 10.1021/jm960666x. J Med Chem. 1997. PMID: 9046330

4

Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.

Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L. Legraverend M, et al. Among authors: leclerc s. Bioorg Med Chem Lett. 1998 Apr 7;8(7):793-8. doi: 10.1016/s0960-894x(98)00097-3. Bioorg Med Chem Lett. 1998. PMID: 9871543

5

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L. Leclerc S, et al. J Biol Chem. 2001 Jan 5;276(1):251-60. doi: 10.1074/jbc.M002466200. J Biol Chem. 2001. PMID: 11013232 Free article.

6

Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.

Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V. Legraverend M, et al. Among authors: leclerc s. Bioorg Med Chem. 1999 Jul;7(7):1281-93. doi: 10.1016/s0968-0896(99)00064-4. Bioorg Med Chem. 1999. PMID: 10465404

7

Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases.

Meijer L, Leclerc S, Leost M. Meijer L, et al. Among authors: leclerc s. Pharmacol Ther. 1999 May-Jun;82(2-3):279-84. doi: 10.1016/s0163-7258(98)00057-6. Pharmacol Ther. 1999. PMID: 10454205 Review.

8

In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.

Giocanti N, Sadri R, Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Favaudon V. Giocanti N, et al. Among authors: leclerc s. Ann N Y Acad Sci. 1999;886:180-2. doi: 10.1111/j.1749-6632.1999.tb09411.x. Ann N Y Acad Sci. 1999. PMID: 10667214 Review. No abstract available.

9

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. Hoessel R, et al. Among authors: leclerc s. Nat Cell Biol. 1999 May;1(1):60-7. doi: 10.1038/9035. Nat Cell Biol. 1999. PMID: 10559866

10

Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors.

Ortega MA, Montoya ME, Zarranz B, Jaso A, Aldana I, Leclerc S, Meijer L, Monge A. Ortega MA, et al. Among authors: leclerc s. Bioorg Med Chem. 2002 Jul;10(7):2177-84. doi: 10.1016/s0968-0896(02)00069-x. Bioorg Med Chem. 2002. PMID: 11983514

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

211 results

Search Page